TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Science has delivered, will the WTO deliver?

  • Brajendra Navnit

    -

Geneva   /   Sat, January 2, 2021   /   03:25 pm
Science has delivered, will the WTO deliver? Vials of AstraZeneca's Covishield inside a lab at Serum Institute of India in Pune, pictured on Nov. 30, 2019. The COVID-19 vaccine is of particular value in developing nations. (Reuters/File photo)

A proposal by India, South Africa and eight other countries calls on the World Trade Organization (WTO) to exempt member countries from enforcing some patents and other Intellectual Property (IP) rights under the organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights, known as TRIPS, for a limited period of time. 

The idea is to ensure that IP rights do not restrict the rapid scaling-up of manufacturing of COVID-19 vaccines and treatments. While a few members have raised concerns about the proposal, a large proportion of the WTO membership supports the proposal. It has also received the backing of various international organizations, multilateral agencies and global civil society.

Unprecedented times call for unorthodox measures. We saw this in the efficacy of strict lockdowns for a limited period, as a policy invention, in curtailing the spread of the pandemic. The International Monetary Fund (IMF) in its October 2020 edition of World Economic Outlook states: “However, the risk of worse growth outcomes than projected remains sizable. If the virus resurges, progress on treatments and vaccines is slower than anticipated, or countries’ access to them remains unequal, economic activity could be lower than expected, with renewed social distancing and tighter lockdowns”. 

The situation appears to be grimmer than predicted, we have already lost 7 percent of economic output from the baseline scenario projected in 2019. That translates to a loss of more than US$6 trillion of global gross domestic product (GDP). Even a 1 percent improvement in global GDP from the baseline scenario would add more than $800 billion in global output, offsetting the loss certainly of a much lower order to a sector of economy on account of the waiver.

Merely a signal to ensure timely and affordable access to vaccines and treatments will work as a big confidence booster for demand revival in the economy. With the emergence of successful vaccines, there appears to be some hope on the horizon. 

But how will these be made accessible and affordable to global population? The fundamental question is whether there will be enough of COVID-19 vaccines to go around. As things stand, even the most optimistic scenarios today cannot assure access to COVID-19 vaccines and therapeutics for the majority of the population, in rich as well as poor countries, by the end of 2021. 

All the members of the WTO have agreed on one account that there is an urgent need to scale-up the manufacturing capacity for vaccines and therapeutics to meet the massive global needs. The TRIPS waiver proposal seeks to fulfil this need by ensuring that IP barriers do not get in the way of such scaling up of manufacturing capacity.

The existing flexibilities under the TRIPS Agreement are not adequate, as these were not designed with pandemics in mind. Compulsory licenses are issued on a country-by-country, case-by-case and product-by-product basis, where every jurisdiction with an IP regime would have to issue separate compulsory licenses, practically making collaboration among countries extremely onerous. 

While we encourage the use of TRIPS flexibilities, the same are time-consuming and cumbersome to implement. Hence, only their use cannot ensure the timely access to affordable vaccines and treatments.

Similarly, we have not seen very encouraging progress on WHO’s COVID19-Technolgoy Access Pool or the C-TAP initiative, which encourages voluntary contribution of IP, technology and data to support the global sharing and scaling-up of the manufacturing of COVID-19 medical products. Voluntary licenses, even where they exist, are shrouded in secrecy. Their terms and conditions are not transparent. Their scope is limited to specific amounts or for a limited subset of countries, thereby encouraging nationalism rather than true international collaboration.

Why is there a need to go beyond existing global cooperation initiatives?

Global cooperation initiatives such as the COVAX Mechanism and the ACT-Accelerator are inadequate to meet the massive global needs of 7.8 billion people. The ACT-A initiative aims to procure 2 billion doses of vaccines by the end of the next year and distribute them fairly around the world. With a two-dose regime, however, this will only cover 1 billion people. That means that even if ACT-A is fully financed and successful, which is not the case presently, there would not be enough vaccines for the majority of the global population.

During the initial few months of the current pandemic, we have seen that shelves were emptied by those who had access to masks, personal protective equipment, sanitizers, gloves and other essential COVID-19 items even without their immediate need.

The same should not happen with vaccines. Eventually, the world was able to ramp up manufacturing of COVID-19 essentials, as there were no barriers hindering that. At present, we need the same pooling of IP rights and know-how for scaling up the manufacturing of vaccines and treatments, which unfortunately has not been forthcoming, necessitating the need for the waiver.

It is the pandemic – an extraordinary, once in a lifetime event – that has mobilized the collaboration of multiple stakeholders. It is knowledge and skills held by scientist, researchers, public health experts and universities that have enabled the cross-country collaborations and enormous public funding that has facilitated the development of vaccines in record time – and not alone IP! 

The TRIPS waiver proposal is a targeted and proportionate response to the exceptional public health emergency that the world faces today. Such a waiver is well within the provisions of Article IX of the Marrakesh Agreement, which established the WTO. It can help in ensuring that human lives are not lost for want of a timely and affordable access to vaccines. 

The adoption of the waiver will also re-establish the WTO’s credibility and show that the multilateral trading system continues to be relevant and can deliver in times of a crisis. Now is the time for WTO members to act and adopt the waiver to save lives and help in getting the economy back on the revival path quickly.

While making the vaccines available was a test of science, making them accessible and affordable is going to be a test of humanity. History should remember us for the AAA rating i.e. for Availability, Accessibility and Affordability of COVID-19 vaccines and treatments and not for a single A rating for Availability only. Our future generations deserve nothing less.

 ***

The writer is the Indian ambassador and permanent representative to the World Trade Organization.

Disclaimer: The opinions expressed in this article are those of the author and do not reflect the official stance of The Jakarta Post.